{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Impactful Breakthroughs","title":"Dave Hine - AVP, Financial Services, Suvoda","html":"","width":"100%","height":180,"duration":1907,"description":"What could clinical research learn from an industry where nothing ships until every system works perfectly in tandem with one another? Dave Hine, AVP of Financial Services at Suvoda, brings a deep background in rigorous systems engineering to today’s episode of Impactful Breakthroughs.\nSuvoda is a global clinical trial technology company which provides a unified software platform to manage complex and time-sensitive clinical studies. In today’s conversation, Dave speaks with host Zach Gobst about what an aerospace engineer noticed when he walked into clinical research and could not stop noticing. Dave studied aerospace engineering, worked flight test and computational fluid dynamics software for the Navy, and joined Greenphire in 2018 as its only sales engineer. Today, he leads the team focused on site payments and budgeting.\nThe two of them get into interoperability and why it stalls in clinical trials, using military technology as the counterexample. Despite having parts manufactured by a handful of private agencies, each element of an F-18 is federally mandated to work seamlessly together. They also cover how COVID was the moment the public finally understood what a clinical trial was, and what survived from the decentralized trial wave.\nThe throughline is a habit most listeners can use directly: treat every process, vendor relationship, and team decision as one system, then ask who is accountable when a piece of it fails. That is the lens Dave brings to site payments, and it holds up as well in a study budget as it does on an aircraft.\n\nTimestamps\n\n00:00 Episode Start \n01:40 Dave’s journey to aerospace engineering\n02:55 Nine years of deep systems experience \n04:10 What brought Dave to clinical trials in 2018 \n05:20 The importance of interoperability\n08:45 Why Dave stayed in clinical trials \n10:50 COVID as a turning point for the entire industry \n12:50 Assume best intent, in both directions \n16:40 Delegation, standards, and leading a team \n23:30 Where AI helps...","thumbnail_url":"https://img.transistorcdn.com/uUl5NjCb9mY4i46LGv4GWJrr5WVj3WxuYTgjBphYmcc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85MDM0/ZDk5OWI2YTcwYWRh/NTM0NzIyODViMjU4/ODlmZS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}